Oksana G. Komissarova

Oksana G. Komissarova

Auto-generated profile, based on publicly available information

Oksana G. Komissarova

Central Tuberculosis Research Institute; Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
OKO. G. Komissarova
O. G. Komissarova
RАR. Yu. Аbdullaev
R. Yu. Аbdullaev
SAS. V. Aleshina
S. V. Aleshina
Частота и характер нежелательных реакций на противотуберкулезные препараты у больных туберкулезом легких и сахарным диабетом

15 October 2018 in Russian Medicine
Verified
Journal Article
Open access
OKO. G Komissarova
O. G Komissarova
RARizvan Yu.O. Abdullaev
Rizvan Yu.O. Abdullaev
SAS. V Aleshina
S. V Aleshina
VRV. V Romanov
V. V Romanov
The aim of the study was to study the clinical manifestations and effectiveness of treatment of pulmonary tuberculosis with multidrug-resistant (MDR M. tuberculosis (MTB) in patients with different types of diabetes mellitus (DM). 66 patients with pulmonary tuberculosis combined with type 1 diabetes mellitus and 48 patients with pulmonary tuberculosis combined with type 2 diabetes were examined. It was found that in patients with type 1 DM, MDR tuberculosis was more often observed in men under 40 years of age, in the form of infiltrative pulmonary tuberculosis with the presence of destruction in lung tissue up to 2 cm in diameter with positive sputum and acute intoxication. In patients with type 2 DM, MDR tuberculosis was more often observed in men over the age of 40 in the form of fibrous-cavernous tuberculosis with the presence of destruction in lung tissue larger than 2 cm in diameter, with positive sputum and moderately severe intoxication. The effectiveness of treatment for negativation sputum in the compared groups did not differ significantly and amounted to 71,2% and 64,7%, respectively. However, to close the caverns in the lung, the treatment was more effective in patients with type 1 diabetes, which is probably due to the peculiarities of the tuberculosis process in this category of patients.

28 August 2023 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
RAR. Yu. Abdullaev
R. Yu. Abdullaev
ATA. M. Tikhonov
A. M. Tikhonov
VSV. A. Shorokhova
V. A. Shorokhova
OKO. G. Komissarova
O. G. Komissarova
The objective: assessment of changes in the parameters of complete blood count, clinical urine tests, and blood chemistry during chemotherapy of patients with MDR/XDR pulmonary tuberculosis receiving the short-course regimen containing bedaquiline, pretomanid, and linezolid (B-Pa-L).Subjects and Methods. 18 patients with MDR/pre-XDR/XDR pulmonary tuberculosis were enrolled into the study. They all received treatment at Central Tuberculosis Research Institute from 2015 to 2022.Results. In the course of chemotherapy of these patients, changes in laboratory test results were noted at different times. Abnormal changes in complete blood count were detected in 10/18 (55,6%) patients during chemotherapy for the 1st time. Hemoglobin levels, erythrocyte and leukocyte counts decreased. Hematuria and bacteriuria were detected by clinical urine test. Proteinuria was observed in almost in half of the patients. Elevated serum potassium level was frequently noted. Blood chemistry demonstrated elevated levels of ALT and AST, which is typical of cytolytic effect on hepatocytes of drugs within chemotherapy. In most cases, all above abnormalities were degree 1 of toxicity and resolved within 2-4 weeks after they were detected. Abnormalities in grade 2-3 of toxicity were mainly observed in patients receiving linezolid at the dose of 1200 mg/day. In most cases, the above abnormalities were detected during the first 4 weeks of chemotherapy.

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
RAR.YU. Abdullaev
R.YU. Abdullaev
OKO.G. Komissarova
O.G. Komissarova
MRM.M. Rybka
M.M. Rybka
EGE.M. Greсov
E.M. Greсov
LSL.A. Semenova
L.A. Semenova
YBYuri Berezovskij
Yuri Berezovskij
Клинико-лабораторные проявления и патологоанатомическая картина тяжелого течения новой коронавирусной инфекции (COVID-19) с летальным исходом

1 January 2020 in Врач
Verified
Journal Article
Closed access
OKO. Komissarova
O. Komissarova
RAR. Abdullaev
R. Abdullaev
SAS. Aleshina
S. Aleshina
В статье приведены современные данные о механизме развития гиперурикемии, ее влияния на различные органы и системы. Проведен анализ литературных данных о частоте и особенностях гиперурикемии у больных туберкулезом как до начала лечения, так и в процессе терапии. Также освещены возможные осложнения при длительной гиперурикемии и подходы к ее комплексному лечению при туберкулезе...

24 December 2023 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
OKO. G. Komissarova
O. G. Komissarova
RAR. Yu. Abdullaev
R. Yu. Abdullaev
SAS. V. Aleshina
S. V. Aleshina
The objective: to develop approaches to selection of optimal chemotherapy regimens in tuberculosis patients with concurrent diabetes mellitus (DM), by studying complications of diabetes mellitus and adverse drug reactions to anti-tuberculosis drugs.Subjects and Methods. 235 adult pulmonary tuberculosis patients with concurrent diabetes were enrolled in the study. Of them, 123 were men (52.3%) and 112 were women (47.7%), and the age of the patients varied from 19 to 78 years old.Results. Complications of diabetes mellitus (DM) were reported in 190/235 (80.8%) patients. Encephalopathy occurred most often – in 147/190 (77.3%) patients, diabetic macroangiopathy developed less often - in 41 (21.6%), followed by diabetic retinopathy – in 20 (10.5%), diabetic nephropathy - in 11 (5.8%), ketoacidosis – in 4 (2.1%), and diabetic foot – in 4 (2.1%). Diabetic macroangiopathy was significantly more often observed in men (66.7%) versus women (31.7%); p<0.01, and diabetic nephropathy was more common in women (81.8%) than men (18.2%); p<0.01. As the age of patients and duration of diabetes increased, the incidence of complications of diabetes also increased. Adverse drug reactions (ADRs) to anti-tuberculosis drugs (TB drugs) occurred in 168/235 (71.4%) patients. ADRs to two or more TB drugs were registered in 140/168 (83.3%) patients. The most frequent irreversible ADRs were caused by the following drugs (of the number of patients taking them): aminoglycosides (58.8%), capreomycin (54.5%), PAS (50.0%), ethambutol (100.0%), cycloserine (40.0%), levofloxacin (33.3%), pyrazinamide (23.3%), terizidone (28.6%), prothionamide (26.3%), linezolid (21.4% ), and moxifloxacin (20.0%).Conclusion. When treating pulmonary tuberculosis in patients with diabetes mellitus, chemotherapy regimens containing aminoglycosides, capreomycin, prothionamide, and pyrazinamide should be avoided. If there is even an initial stage of retinopathy, ethambutol should be avoided. Patients with encephalopathy should be switched from cycloserine to terizidone.